Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2012 1
2013 4
2014 8
2015 2
2016 9
2017 14
2018 18
2019 23
2020 24
2021 10
2022 7
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31390166

101 results

Results by year

Filters applied: . Clear all
Page 1
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world practice: Results of 12-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
Utsunomiya K, Senda M, Kakiuchi S, Kameda H, Tamura M, Kurihara Y, Gunji R, Fujii S, Kaku K. Utsunomiya K, et al. J Diabetes Investig. 2020 Jan;11(1):132-141. doi: 10.1111/jdi.13097. Epub 2019 Jul 8. J Diabetes Investig. 2020. PMID: 31197929 Free PMC article.
Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
Utsunomiya K, Senda M, Kakiuchi S, Kameda H, Tamura M, Kurihara Y, Gunji R, Fujii S, Fujiwara H, Kaku K. Utsunomiya K, et al. J Diabetes Investig. 2019 Sep;10(5):1272-1283. doi: 10.1111/jdi.13017. Epub 2019 Mar 6. J Diabetes Investig. 2019. PMID: 30702214 Free PMC article.
Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study.
Terauchi Y, Fujiwara H, Kurihara Y, Suganami H, Tamura M, Senda M, Gunji R, Kaku K. Terauchi Y, et al. J Diabetes Investig. 2019 Nov;10(6):1518-1526. doi: 10.1111/jdi.13066. Epub 2019 May 28. J Diabetes Investig. 2019. PMID: 31033218 Free PMC article. Clinical Trial.
Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.
Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K, Tanizawa Y, Araki E, Ueda M, Suganami H, Watanabe D; Tofogliflozin 003 Study Group. Kaku K, et al. Cardiovasc Diabetol. 2014 Mar 28;13:65. doi: 10.1186/1475-2840-13-65. Cardiovasc Diabetol. 2014. PMID: 24678906 Free PMC article. Clinical Trial.
101 results